{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:07:19Z","timestamp":1795230439102,"version":"4.10.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11255-021-02802-0","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T19:02:51Z","timestamp":1616180571000},"page":"1067-1072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB)"],"prefix":"10.1007","volume":"53","author":[{"given":"Jessica","family":"Ton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrin","family":"Downing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-7370","authenticated-orcid":false,"given":"Eboo","family":"Versi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"van Uem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Ephraim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lucente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen J, Cundiff G, Abrams P et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4","journal-title":"World J Urol"},{"key":"2802_CR2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11136-004-0706-1","volume":"14","author":"KS Coyne","year":"2005","unstructured":"Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849\u2013855. https:\/\/doi.org\/10.1007\/s11136-004-0706-1","journal-title":"Qual Life Res"},{"key":"2802_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","volume":"110","author":"A Wagg","year":"2012","unstructured":"Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience: Persistence with antimuscarinic therapy in OAB. BJU Int 110:1767\u20131774. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11023.x","journal-title":"BJU Int"},{"key":"2802_CR4","doi-asserted-by":"publisher","unstructured":"Duthie JB, Vincent M, Herbison GP et al (2011) Botulinum toxin injections for adults with overactive bladder syndrome. In: The cochrane database of systematic reviews. John Wiley & Sons, Ltd, Chichester. https:\/\/doi.org\/10.1002\/14651858.CD005493.pub3","DOI":"10.1002\/14651858.CD005493.pub3"},{"key":"2802_CR5","unstructured":"Allergan (1989) Botox\u00ae (OnabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103000s5302lbl.pdf. Revised 6 2019. Accessed 6 2019"},{"key":"2802_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","volume":"178","author":"HC Kuo","year":"2007","unstructured":"Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 178:1359\u20131363. https:\/\/doi.org\/10.1016\/j.juro.2007.05.136","journal-title":"J Urol"},{"key":"2802_CR7","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/nau.21054","volume":"30","author":"HC Kuo","year":"2011","unstructured":"Kuo HC (2011) Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30:1242\u20131248. https:\/\/doi.org\/10.1002\/nau.21054","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"2802_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/21681805.2017.1362467","volume":"51","author":"M Szczypior","year":"2017","unstructured":"Szczypior M, Po\u0142om W, Markuszewski M et al (2017) Overactive bladder treatment: application of methylene blue to improve the injection technique of onabotulinum toxin A. Scand J Urol 51(6):474\u2013478. https:\/\/doi.org\/10.1080\/21681805.2017.1362467","journal-title":"Scand J Urol"},{"key":"2802_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/01.AOG.0000284445.68789.ee","volume":"110","author":"A Gehrich","year":"2007","unstructured":"Gehrich A, Stany MP, Fischer JR et al (2007) Establishing a mean postvoid residual volume in asymptomatic perimenopausal and postmenopausal women. Obstet Gynecol 110:827\u2013832. https:\/\/doi.org\/10.1097\/01.AOG.0000284445.68789.ee (PMID: 17906016)","journal-title":"Obstet Gynecol"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1756287216672180","volume":"9","author":"D Eldred-Evans","year":"2017","unstructured":"Eldred-Evans D, Sahai A (2017) Medium-to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 9:3\u201310. https:\/\/doi.org\/10.1177\/1756287216672180","journal-title":"Ther Adv Urol"},{"key":"2802_CR11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00192-015-2751-4","volume":"26","author":"N Chohan","year":"2015","unstructured":"Chohan N, Hilton P, Brown K, Dixon L (2015) Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J 26:1605\u20131612. https:\/\/doi.org\/10.1007\/s00192-015-2751-4","journal-title":"Int Urogynecol J"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2016.10.109","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189:2186\u20132193. https:\/\/doi.org\/10.1016\/j.juro.2016.10.109 (Epub 2016 Dec 22 PMID: 28012773)","journal-title":"J Urol"},{"key":"2802_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S et al (2013) OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64:249\u2013256. https:\/\/doi.org\/10.1016\/j.eururo.2013.04.001 (Epub 2013 Apr 10 PMID: 23608668)","journal-title":"Eur Urol"},{"key":"2802_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sc.2015.143","volume":"54","author":"C Hui","year":"2016","unstructured":"Hui C, Keji X, Chonghe J et al (2016) Combined detrusor-trigone BTA-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord 54:46\u201350. https:\/\/doi.org\/10.1038\/sc.2015.143","journal-title":"Spinal Cord"},{"key":"2802_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00345-017-2121-6","volume":"36","author":"JK Jo","year":"2018","unstructured":"Jo JK, Kim KN, Kim DW et al (2018) The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. Word J Urol 36:305\u2013317. https:\/\/doi.org\/10.1007\/s00345-017-2121-6","journal-title":"Word J Urol"},{"key":"2802_CR16","first-page":"3291","volume":"13","author":"A Lucioni","year":"2006","unstructured":"Lucioni A, Rapp DE, Gong EM et al (2006) Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 13:3291\u20133295","journal-title":"Can J Urol"},{"key":"2802_CR17","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","volume":"184","author":"TA Abdel-Meguid","year":"2010","unstructured":"Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder-to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184:2423\u20132428. https:\/\/doi.org\/10.1016\/j.juro.2010.08.028","journal-title":"J Urol"},{"key":"2802_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","volume":"61","author":"RP Manecksha","year":"2012","unstructured":"Manecksha RP, Cullen IM, Ahmad S et al (2012) Prospective randomized controlled trial comparing trigone-sparing versus trigone-including intra-detrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61:928\u2013935. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.043","journal-title":"Eur Urol"},{"key":"2802_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000351037","volume":"91","author":"Y Cui","year":"2013","unstructured":"Cui Y, Wang L, Liu L et al (2013) Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 91:429\u2013438. https:\/\/doi.org\/10.1159\/000351037","journal-title":"Urol Int"},{"key":"2802_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrn2401","volume":"9","author":"CJ Fowler","year":"2008","unstructured":"Fowler CJ, Griffiths D, de Groat WC (2008) The neural control of micturition. Nat Rev Neurosci 9:453\u2013466. https:\/\/doi.org\/10.1038\/nrn2401","journal-title":"Nat Rev Neurosci"},{"key":"2802_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1464-410x.2003.04667.x","volume":"93","author":"JI Gillespie","year":"2004","unstructured":"Gillespie JI (2004) The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int 93:478\u2013483. https:\/\/doi.org\/10.1111\/j.1464-410x.2003.04667.x","journal-title":"BJU Int"},{"issue":"8","key":"2802_CR22","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/nau.24110","volume":"38","author":"ES Rovner","year":"2019","unstructured":"Rovner ES, Versi E, Le Mai T et al (2019) One-year results with selective bladder denervation in women with refractory overactive bladder. Neurourol Urodyn 38(8):2178\u20132184. https:\/\/doi.org\/10.1002\/nau.24110","journal-title":"Neurourol Urodyn"},{"key":"2802_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/nau.23052","volume":"36","author":"MA Avallone","year":"2017","unstructured":"Avallone MA, Sack BS, El-Arabi A et al (2017) Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity. Neurourol Urodyn 36:1104\u20131107. https:\/\/doi.org\/10.1002\/nau.23052","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"2802_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","volume":"27","author":"U Mehnert","year":"2009","unstructured":"Mehnert U, Boy S, Schmid M, Reitz A et al (2009) A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 27(3):397\u2013403. https:\/\/doi.org\/10.1007\/s00345-008-0362-0","journal-title":"World J Urol"},{"key":"2802_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/nau.23560","volume":"37","author":"J Fugett 2nd","year":"2018","unstructured":"Fugett J 2nd, Phillips L, Tobin E et al (2018) Selective bladder denervation for overactive bladder (OAB) syndrome: from concept to healing outcomes using the ovine model. Neurourol Urodyn 37:2097\u20132105. https:\/\/doi.org\/10.1002\/nau.23560","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"2802_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4111\/icu.2019.60.1.40","volume":"60","author":"R Syan","year":"2019","unstructured":"Syan R, Briggs MA, Olivas JC, Srivastava S, Comiter CV, Dobberfuhl, (2019) Transvaginal ultrasound guided trigone and bladder injection: a cadaveric feasibility study for a novel route of intradetrusor chemodenervation. Investig Clin Urol 1 60(1):40\u201345. https:\/\/doi.org\/10.4111\/icu.2019.60.1.40","journal-title":"Investig Clin Urol 1"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02802-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02802-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02802-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T14:16:00Z","timestamp":1621865760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02802-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02802-0","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors: Drs. Ton, Downing, Van Uem and Ephraim declare they have no financial interests.\u00a0Dr. Versi has been a consultant for Hologic Inc. and is inventor of US Patent No. 8,029,496. Dr. Murphy has been a consultant for Boston Scientific and expert witness for J&J. Dr. Lucente has received research funding from Advanced Tactile Imaging, Boston Scientific, Coloplast and Valencia; speaking honoraria from Allergan, Boston Scientific, Coloplast and Duchesnay; consultant for Contura; expert witness for American Medical Systems and Bard.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Institutional ethical approval was obtained prior to performing this retrospective chart review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}